The potential of circulating microRNA (miRNA) levels as a biomarker in drug development: An analysis of tumor-serum samples from patients on a phase I trial of saracatinib-paclitaxel (P)-carboplatin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback